Brain Cancer Trial, Recruiting NCT06796543 Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT06796543
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group A (newly diagnosed sarcoma):

  • People who are under 39 years old at the time of joining the trial
  • People who are reasonably physically well and able to carry out daily activities (as measured by standard medical scoring tools)
  • People who have been newly diagnosed with a soft tissue or bone sarcoma (confirmed by tissue sample or molecular testing) located anywhere in the body
  • People whose cancer has spread to other parts of the body, with at least one measurable spot of spread (larger than 3mm on a CT scan) that is separate from the main tumour, with the CT scan taken within 3 weeks of starting treatment

Group B (returning or worsening sarcoma):

  • People who are reasonably physically well and able to carry out daily activities (as measured by standard medical scoring tools)
  • People whose soft tissue or bone sarcoma (first diagnosed before age 39) has been confirmed to have grown or spread — either at a new location or at a previously known site
  • People whose cancer has spread to other parts of the body, with at least one measurable spot of spread larger than 3mm on a CT scan, separate from the main tumour
  • People for whom radiation therapy to at least one site has been recommended as part of their second round of treatment

Who may not be able to join:

Group A:

  • People whose cancer has spread to the brain or the fluid and membranes surrounding the brain or spinal cord
  • People showing signs that the spinal cord is being compressed in a way that requires urgent radiation treatment
  • People who have a positive bone marrow biopsy result (when the primary tumour is not in the pelvis) and more than eight spots of cancer spread to the bones (note: all lung spots together count as just one bone metastasis for this rule)
  • People who have any cancer spread that cannot be accurately measured, such as spread to the fluid around the brain or spine, fluid in the abdomen, or fluid around the lungs or heart
  • People who are pregnant

Group B:

  • People whose cancer has spread to the brain or the fluid and membranes surrounding the brain or spinal cord
  • People showing signs that the spinal cord is being compressed in a way that requires urgent radiation treatment
  • People who have any cancer spread that cannot be accurately measured, such as spread to the fluid around the brain or spine, fluid in the abdomen, or fluid around the lungs or heart
  • People who are pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sahaja Acharya, MD, SKCCC Johns Hopkins Medical Institution

Phone: 4432877889

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
25 March 2025
Est. completion
1 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Event free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov